Pluripotent stem cell–derived NK cells with high-affinity ...

HEMATOPOIESIS AND STEM CELLS| FEBRUARY 6, 2020

Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity

Huang Zhu  , Robert H. Blum  , Ryan Bjordahl  , Svetlana Gaidarova  , Paul Rogers  , Tom Tong Lee  , Ramzey Abujarour  , Gregory B. Bonello  , Jianming Wu  , Pei-Fang Tsai  , Jeffrey S. Miller  , Bruce Walcheck  , Bahram Valamehr  , Dan S. Kaufman

Blood (2020) 135 (6): 399–410.

https://doi.org/10.1182/blood.2019000621

Key Points

Human pluripotent stem cells provide a novel platform to produce engineered off-the-shelf NK cells with efficient antitumor activity.

Human iPSC-NK cells with high-affinity noncleavable CD16a enable antibodies to more efficiently target NK cells to diverse tumor types.

Abstract

Antibody-dependent cellular cytotoxicity (ADCC) is a key effector mechanism of natural killer (NK) cells that is mediated by therapeutic monoclonal antibodies (mAbs). This process is facilitated by the Fc receptor CD16a on human NK cells. CD16a appears to be the only activating receptor on NK cells that is cleaved by the metalloprotease a disintegrin and metalloproteinase-17 upon stimulation. We previously demonstrated that a point mutation of CD16a prevents this activation-induced surface cleavage. This noncleavable CD16a variant is now further modified to include the high-affinity noncleavable variant of CD16a (hnCD16) and was engineered into human induced pluripotent stem cells (iPSCs) to create a renewable source for human induced pluripotent stem cell–derived NK (hnCD16-iNK) cells. Compared with unmodified iNK cells and peripheral blood–derived NK (PB-NK) cells, hnCD16-iNK cells proved to be highly resistant to activation-induced cleavage of CD16a. We found that hnCD16-iNK cells were functionally mature and exhibited enhanced ADCC against multiple tumor targets. In vivo xenograft studies using a human B-cell lymphoma demonstrated that treatment with hnCD16-iNK cells and anti-CD20 mAb led to significantly improved regression of B-cell lymphoma compared with treatment utilizing anti-CD20 mAb with PB-NK cells or unmodified iNK cells. hnCD16-iNK cells, combined with anti-HER2 mAb, also mediated improved survival in an ovarian cancer xenograft model. Together, these findings show that hnCD16-iNK cells combined with mAbs are highly effective against hematologic malignancies and solid tumors that are typically resistant to NK cell–mediated killing, demonstrating the feasibility of producing a standardized off-the-shelf engineered NK cell therapy with improved ADCC properties to treat malignancies that are otherwise refractory.

Subjects:

Hematopoiesis and Stem Cells, Immunobiology and Immunotherapy

Topics:

ink, lymphoma, natural killer cells, neoplasms, stem cells, pluripotent, affinity, antibody-dependent cell cytotoxicity,monoclonal antibodies, cancer, fc receptors

© 2020 by The American Society of HematologyThis program is developed by Focus Insight with the permission of American Society of Hematology, Inc. The content are excerpted from the journal Blood. Copyright © 2019 The American Society of Hematology. All rights reserved. 「American Society of Hematology」, 「ASH」 and the ASH Logo are registered trademarks of the American Society of Hematology.